Drugs to treat rare disorders and genetic diseases are particularly demanding to develop, and biotechnology companies predominantly have been the firms that have stepped up to that challenge.

Arpida's Shares Sink 53% on Negative Review of Iclaprim

Nov. 26, 2008

By Donna Young

Waxman Unseats Dingell from Energy & Commerce Committee

Nov. 24, 2008

By Donna Young

FDA Experts Give Thumbs Down to Arpida, Targanta Antibiotics

Nov. 21, 2008

By Donna Young

COLLEGE PARK, Md. - Federal advisers Thursday said Arpida AG failed to show in clinical trials that its experimental antibiotic iclaprim was safe and effective for treating patients with complicated skin and skin structure infections (cSSSIs). (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld Science
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...